Emergent Health Corp. Overview
Industry: Drug Manufacturers-Specialty & Generic
Sector: Healthcare
Emergent Health Corp. develops and sells regenerative medicine, neutraceuticals, and phytonutritionals. Its products comprise Vita-Stim, a nutrient that enhances the immune system, nourishes stem cells, and maintains health; Neuvitale, which nourishes stem cells and acts as a methyl donor to protect DNA; Hungarest, a diet aid that controls appetite in the brain and stomach; EmergentO2, water oxygenator, which increases oxygen in the blood stream; and products for reducing facial wrinkles. The company distributes its products through health food stores, pharmacies, and various other retail outlets throughout the United States and internationally. Emergent Health Corp. is based in King of Prussia, Pennsylvania. As of August 26, 2014, Emergent Health Corp was taken private.
Emergent Health Corp. is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.
Score
Price History & Performance
Review Emergent Health Corp. in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.
Recent News
Emergent Health Corp. Competitors
Emergent Health Corp. operates in the Drug Manufacturers-Specialty & Generic industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.
Earnings Per Share
EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.
Continue the analysis
Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.
View plans